Eli Lilly: new class of painkiller gets fast-track status.
(CercleFinance.com) - Pfizer and Eli Lilly said on Tuesday that U.
S. regulators have agreed to speed the review of their experimental painkiller.
More specifically, the Food and Drug Administration (FDA) has granted a "fast track" designation for tanezumab in the treatment of chronic pain in patients with osteoarthritis and chronic low back pain.
If approved, tanezumab would be the first in a new class of non-opioid chronic pain medications, the two biopharmaceutical companies said in a joint press release.
A phase-3 global clinical development programme is currently ongoing and includes six studies in approximately 7,000 patients with osteoarthritis and chronic low back pain or cancer pain.
Results are projected to begin reporting out in 2018.
In 2013, Pfizer and Lilly entered into a worldwide co-development and co-commercialisation agreement for the molecule.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
S. regulators have agreed to speed the review of their experimental painkiller.
More specifically, the Food and Drug Administration (FDA) has granted a "fast track" designation for tanezumab in the treatment of chronic pain in patients with osteoarthritis and chronic low back pain.
If approved, tanezumab would be the first in a new class of non-opioid chronic pain medications, the two biopharmaceutical companies said in a joint press release.
A phase-3 global clinical development programme is currently ongoing and includes six studies in approximately 7,000 patients with osteoarthritis and chronic low back pain or cancer pain.
Results are projected to begin reporting out in 2018.
In 2013, Pfizer and Lilly entered into a worldwide co-development and co-commercialisation agreement for the molecule.
Copyright (c) 2017 CercleFinance.com. All rights reserved.